Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 5, 2025Hematology

Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T - cell persistence in ALL

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMaria GabelliSGSara Ghorashian

Discussion

Loading...

Member takes

Overview

Analysis highlights infusion strategies and hematopoietic stem cell transplantation to address relapse in pediatric ALL, indicating potential benefits of total body irradiation and tyrosine kinase use

Key Points

  • Relapse risk reduction is essential after CAR T cell infusion in pediatric ALL patients.
  • Children with early B-cell recovery post-infusion should consider hematopoietic stem cell transplantation.
  • Total body irradiation offers potential benefits for eligible patients undergoing HSCT in ALL treatment.
  • Clinical trials may further clarify treatment options for relapsed pediatric ALL cases.],

Cite This Study

Gabelli et al. (2025) studied this question.

synapsesocial.com/papers/6940224e2d562116f28fc115https://doi.org/10.1182/hematology.2025000734
View Full Paper
Ask AI
Bookmark
Share